Literature DB >> 15168600

Successful treatment of chronic disseminated candidiasis with caspofungin and itraconazole in a patient with progressive acute leukemia and prolonged neutropenia.

K Hübel1, J Chemnitz, H G Brochhagen, O A Cornely.   

Abstract

Severe fungal infections remain a significant cause of morbidity and mortality in neutropenic patients undergoing dose-intensive chemotherapy for malignant diseases. Chronic disseminated candidiasis (CDC) is a life-threatening complication in neutropenic patients because of the lack of responsive hematopoietic precursor cells. Resolution of Candida organ lesions after hematopoietic reconstitution may take months. Here, we report the case of a 19-year-old neutropenic woman with relapsed acute myelogenous leukemia and candidiasis of liver, spleen, and kidneys. Antifungal treatment was initiated using fluconazole and caspofungin but was changed to itraconazole and caspofungin. Despite elevated C-reactive protein (CRP) levels and detectable Candida organ lesions, antileukemic therapy was restarted with interleukin 2 at the same time as antimicrobial treatment. Eight weeks after the start of interleukin therapy, CRP levels and organ lesions were decreased significantly irrespective of continuing neutropenia. This case report describes the successful treatment of CDC during neutropenia using combination antifungal therapy and suggests controlled studies to establish optimal therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15168600     DOI: 10.1532/ijh97.e0315

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  20 in total

1.  Successful treatment of chronic disseminated candidiasis with fluconazole and a granulocyte-macrophage colony-stimulating factor combination.

Authors:  L Rókusz; L Liptay; K Kádár
Journal:  Scand J Infect Dis       Date:  2001

2.  Hepatosplenic candidiasis after neutropenic phase of acute leukaemia.

Authors:  M Colović; V Lazarević; R Colović; G Janković; N Suvajdzić; A Bogdanović; J Bila
Journal:  Med Oncol       Date:  1999-07       Impact factor: 3.064

3.  A phase II study of interleukin-2 in 49 patients with relapsed or refractory acute leukemia.

Authors:  D Maraninchi; N Vey; P Viens; A M Stoppa; E Archimbaud; M Attal; D Baume; R Bouabdallah; F Demeoq; J Fleury; M Michallet; D Olive; J Reiffers; D Sainty; A Tabilio; P Tiberghien; M Brandely; T Hercend; D Blaise
Journal:  Leuk Lymphoma       Date:  1998-10

4.  Modulation of neutrophil-mediated activity against the pseudohyphal form of Candida albicans by granulocyte colony-stimulating factor (G-CSF) administered in vivo.

Authors:  J M Gaviria; J A van Burik; D C Dale; R K Root; W C Liles
Journal:  J Infect Dis       Date:  1999-05       Impact factor: 5.226

5.  Successful treatment of hepatosplenic candidiasis in an elderly patient with acute myeloid leukemia using liposomal daunorubicin and fluconazole.

Authors:  G Quintini; V Barbera; R Gambino; V Spadola; V Minardi; G Mariani
Journal:  Haematologica       Date:  2001-08       Impact factor: 9.941

6.  Chronic disseminated candidiasis in patients with hematologic malignancies. Clinical features and outcome of 29 episodes.

Authors:  Livio Pagano; Luca Mele; Luana Fianchi; Lorella Melillo; Bruno Martino; Domenico D'Antonio; Maria Elena Tosti; Brunella Posteraro; Maurizio Sanguinetti; Giulio Trapè; Francesco Equitani; Mario Carotenuto; Giuseppe Leone
Journal:  Haematologica       Date:  2002-05       Impact factor: 9.941

7.  The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. An autopsy study of 355 patients.

Authors:  J H van Burik; W Leisenring; D Myerson; R C Hackman; H M Shulman; G E Sale; R A Bowden; G B McDonald
Journal:  Medicine (Baltimore)       Date:  1998-07       Impact factor: 1.889

Review 8.  The first echinocandin: caspofungin.

Authors:  O A Cornely; Karina Schmitz; Sabine Aisenbrey
Journal:  Mycoses       Date:  2002       Impact factor: 4.377

9.  How long can we give interleukin-2? Clinical and immunological evaluation of AML patients after 10 or more years of IL2 administration.

Authors:  G Meloni; S M Trisolini; S Capria; G F Torelli; E Baldacci; C Torromeo; G Valesini; F Mandelli
Journal:  Leukemia       Date:  2002-10       Impact factor: 11.528

10.  Successful treatment of hepatosplenic candidiasis through repeated cycles of chemotherapy and neutropenia.

Authors:  T J Walsh; P O Whitcomb; S G Revankar; P A Pizzo
Journal:  Cancer       Date:  1995-12-01       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.